StockNews.com Begins Coverage on RedHill Biopharma (NASDAQ:RDHL)

StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research note released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Price Performance

NASDAQ RDHL opened at $0.47 on Monday. The firm’s 50-day moving average is $0.47 and its two-hundred day moving average is $0.75. RedHill Biopharma has a 12 month low of $0.26 and a 12 month high of $3.28.

Institutional Trading of RedHill Biopharma

Several hedge funds have recently made changes to their positions in RDHL. Armistice Capital LLC acquired a new stake in RedHill Biopharma in the third quarter valued at approximately $369,000. Sabby Management LLC purchased a new position in RedHill Biopharma in the third quarter valued at approximately $324,000. Finally, Gagnon Securities LLC increased its stake in RedHill Biopharma by 32.1% in the first quarter. Gagnon Securities LLC now owns 118,360 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 28,771 shares during the last quarter. Institutional investors and hedge funds own 7.20% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.